| Income Statement | 2026-06-30 | 2026-03-31 | ||
|---|---|---|---|---|
| Research and development | 24,729 | 22,889 | ||
| General and administrative | 6,561 | 5,020 | ||
| Total operating expenses | 31,290 | 27,909 | ||
| Loss from operations | -31,290 | -27,909 | ||
| Interest income | 2,696 | 1,125 | ||
| Interest expense | 272 | 98 | ||
| Other income (expense) | -69 | 13 | ||
| Total other income | 2,355 | 1,040 | ||
| Net loss | -28,935 | -26,869 | ||
| Basic EPS | -0.98 | -21.83 | ||
| Diluted EPS | -0.98 | -21.83 | ||
| Basic Average Shares | 29,650,660 | 1,230,698 | ||
| Diluted Average Shares | 29,650,660 | 1,230,698 | ||
Avalyn Pharma Inc. (AVLN)
Avalyn Pharma Inc. (AVLN)